Personalized medical device for the diagnosis and treatment of ADHD based on EEG biomarkers and Neurofeedback Training

## Fact Sheet

### Project Information

**NEWROFEED**  
Grant agreement ID: 684809

**Funded under**  
SOCIETAL CHALLENGES - Health, demographic change and well-being

**Total cost**  
€ 3 600 632,50

**EU contribution**  
€ 3 600 632,50

**Coordinated by**  
MENSIA TECHNOLOGIES  
France

**DOI**  
[10.3030/684809](http://10.3030/684809)

**Closed project**

**EC signature date**  
11 October 2015

**Start date**  
1 October 2015  
**End date**  
31 March 2018

### Objective

NEWROFEED aims at setting a new standard of care for children suffering from Attention Deficit Hyperactivity Disorder (ADHD). ADHD@Home is the diagnosis and treatment medical device, developed by Mensia in project NEWROFEED, to achieve
this goal. In order to optimise success rates, ADHD@Home is based on an EEG biomarker-based personalised medicine approach to treat ADHD children with state-of-the-art personalized Neurofeedback Training. This patient-centered solution is delivered at home, with supervision by ADHD specialists. As an efficacious alternative to treatment by psychoactive medication, the expected clinical outcomes include normalized social behaviour and improved school performance. ADHD@Home delivers physiological lasting normalization of brain activity, using the child’s endogenous neuronal plasticity, to resolve his or her attention and hyperactivity problems. Its unique technology and design enable it to achieve two critical clinical objectives:

1. To identify the root cause of the ADHD for a given child by quantifying, in real-time, deviations in EEG oscillation biomarkers allowing the clinician to select and adjust the Neurofeedback protocols.

2. To deliver the personalized Neurofeedback protocols on an affordable and user-friendly device, enabling optimal training at home under remote medical supervision. This clinical breakthrough is made possible by Mensia’s cloud-based real time quantitative EEG analysis technology. ADHD@Home will be validated for efficacy in the NEWROFEED Clinical Trial. This will pave the way for a successful commercial launch in 2018 to deliver on our promise of efficacious physiological treatment for millions of ADHD children.

Thanks to NEWROFEED, Mensia will become a world leader in the field of EEG-based personalised treatment of Central Nervous System disorders; capitalizing on the clinical success of its ADHD@Home device that will generate 65M€ in cumulative revenues by 2022.

**Fields of science**

- natural sciences → biological sciences → neurobiology
- medical and health sciences → health sciences → public health
- medical and health sciences → clinical medicine → psychiatry
- medical and health sciences → basic medicine → pharmacology and pharmacy → pharmaceutical drugs
- medical and health sciences → health sciences → personalized medicine

**Programme(s)**

H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being

H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials

H2020-EU.3.1.3. - Treating and managing disease
Topic(s)

PHC-12-2015 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-2-2015

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

MENSA TECHNOLOGIES

Net EU contribution

€ 3 600 632,50

Address

Place du granier
35571 Chantepie
France

SME

Yes

Region

Bretagne > Bretagne > Ille-et-Vilaine

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Contact the organisation
Participation in EU R&I programmes
HORIZON collaboration network
Other funding

€ 0,00

**Last update:** 10 March 2023

**Permalink:** [https://cordis.europa.eu/project/id/684809](https://cordis.europa.eu/project/id/684809)

European Union, 2023